WACKER Will Not Produce an mRNA Vaccine for CureVac

Munich, Sep 14, 2021

CureVac N.V., a company based in Tübingen, Germany, needs less production capacity for CVnCOV, its mRNA vaccine candidate against Covid-19. As a result, it has terminated its contract with Wacker Chemie AG.

This will not have any significant impact on WACKER BIOSOLUTIONS’ sales and earnings in 2021. “And it does not change our medium-term targets for the Biosolutions division either,” said Dr. Susanne Leonhartsberger, the division’s head. “We are confident that we can provide other customers with the freed-up capacity for their mRNA and other molecules in the future,” added Dr. Susanne Leonhartsberger. WACKER’s site in Amsterdam has manufactured vaccines for customers for more than 20 years.


contact image

Wacker Chemie AG
Corporate Communications
Joerg Hettmann

Send Message